Novozymes As B Stock Fundamentals
| NVZMF Stock | USD 59.48 1.98 3.44% |
Novozymes AS B fundamentals help investors to digest information that contributes to Novozymes A/S's financial success or failures. It also enables traders to predict the movement of Novozymes Pink Sheet. The fundamental analysis module provides a way to measure Novozymes A/S's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novozymes A/S pink sheet.
Novozymes |
Novozymes AS B Company Return On Equity Analysis
Novozymes A/S's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novozymes A/S Return On Equity | 0.28 |
Most of Novozymes A/S's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS B is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novozymes AS B has a Return On Equity of 0.2789. This is 69.35% lower than that of the Basic Materials sector and 95.26% lower than that of the Specialty Chemicals industry. The return on equity for all United States stocks is 189.97% lower than that of the firm.
Novozymes AS B Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novozymes A/S's current stock value. Our valuation model uses many indicators to compare Novozymes A/S value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novozymes A/S competition to find correlations between indicators driving Novozymes A/S's intrinsic value. More Info.Novozymes AS B is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.38 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novozymes AS B is roughly 2.63 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novozymes A/S's earnings, one of the primary drivers of an investment's value.Novozymes Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novozymes A/S's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novozymes A/S could also be used in its relative valuation, which is a method of valuing Novozymes A/S by comparing valuation metrics of similar companies.Novozymes is currently under evaluation in return on equity category among its peers.
Novozymes Fundamentals
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Shares Owned By Insiders | 8.04 % | |||
| Shares Owned By Institutions | 42.30 % | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X | |||
| Price To Sales | 0.82 X | |||
| Revenue | 17.55 B | |||
| Gross Profit | 9.59 B | |||
| EBITDA | 6.12 B | |||
| Net Income | 3.68 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Current Ratio | 1.20 X | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Price To Earnings To Growth | 3.85 X | |||
| Target Price | 28.3 | |||
| Number Of Employees | 6.44 K | |||
| Beta | 0.4 | |||
| Market Capitalization | 13.95 B | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Working Capital | 2.67 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.38 % | |||
| Net Asset | 27.98 B | |||
| Last Dividend Paid | 6.0 |
About Novozymes A/S Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novozymes AS B's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes AS B based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Novozymes Pink Sheet
Novozymes A/S financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes A/S security.